SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant

BRAF mutations result in constitutively active BRAF kinase activity and increased extracellular signal-regulated kinase (ERK) signaling and cell proliferation. Initial studies have shown that BRAF mutations occur at a high frequency in melanocytic nevi and metastatic lesions, but recent data have revealed much lower incidence of these mutations in early-stage melanoma, implying that other factors may contribute to melanoma pathogenesis in a wild-type (WT) BRAF context. To identify such contributing factors, we used microarray gene expression profiling to screen for differences in gene expression between a panel of melanocytic and melanoma cell lines with WT BRAF and a group of melanoma cell lines with the V599E BRAF mutation. We found that SPRY2, an inhibitor homologous to SPRY4, which was previously shown to suppress Ras/ERK signaling via direct binding to Raf-1, had reduced expression in WT BRAF cells. Using small interfering RNA-mediated SPRY2 knockdown, we showed that SPRY2 acts as an inhibitor of ERK signaling in melanocytes and WT BRAF melanoma cells, but not in cell lines with the V599E mutation. We also show that SPRY2 and SPRY4 directly bind WT BRAF but not the V599E and other exon 15 BRAF mutants. These data suggest that SPRY2, an inhibitor of ERK signaling, may be bypassed in melanoma cells either by down-regulation of its expression in WT BRAF cells, or by the presence of the BRAF mutation.

[1]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[2]  D. Morton,et al.  Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas , 2004, Clinical Cancer Research.

[3]  G. Christofori,et al.  Sprouty proteins: antagonists of endothelial cell signaling and more , 2003, Thrombosis and Haemostasis.

[4]  Meenhard Herlyn,et al.  BRAF as a potential therapeutic target in melanoma and other malignancies. , 2003, Cancer cell.

[5]  Rui Qiao,et al.  BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. , 2003, Cancer research.

[6]  G. Christofori Split personalities: the agonistic antagonist Sprouty , 2003, Nature Cell Biology.

[7]  A. Yoshimura,et al.  Mammalian Sprouty4 Suppresses Ras-Independent ERK Activation by Binding to Raf1 , 2003, Cell cycle.

[8]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[9]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[10]  E. Nishida,et al.  Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway , 2002, Nature Cell Biology.

[11]  G. Scott Rac and rho: the story behind melanocyte dendrite formation. , 2002, Pigment cell research.

[12]  Isabelle Gross and Jonathan D. Licht Sprouty Proteins, A New Family of Receptor Tyrosine Kinase Inhibitors , 2002 .

[13]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[14]  D. Bar-Sagi,et al.  The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Jonathan D. Licht,et al.  Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation* , 2001, The Journal of Biological Chemistry.

[16]  M. Kohno,et al.  ERK pathway positively regulates the expression of Sprouty genes. , 2001, Biochemical and biophysical research communications.

[17]  N. Hacohen,et al.  sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways , 1998, Cell.

[18]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.